In vitro susceptibility of vaginal Candida albicans to antifungal drugs in Abidjan (Ivory Coast);Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques à Abidjan (Côte d'Ivoire)

Journal de Mycologie Medicale

Volumn 22, Issue 2, 2012, Pages 129-133

  Djohan, V ^a,c   Angora, K E ^b   Vanga Bosson, A H ^a,b   Konate A ^a   Kassi, F K ^a,d   Yavo, W ^a,c   Kiki Barro, P C ^a   Menan, H ^a,d   Kone M ^a,b  

^a UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^b INSTITUT PASTEUR DE CÔTE D'IVOIRE   (Côte d’Ivoire)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Côte d’Ivoire)

^d Centre de diagnostic et de recherche sur le Sida et les maladies opportunistes   (Côte d’Ivoire)

Author keywords

5 fluorocytosine; Amphotericine B; C. albicans; Fluconazole; In vitro susceptibility; Itraconazole; Vaginal candidosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BURNING SENSATION; CANDIDA ALBICANS; CORRELATION ANALYSIS; COTE D'IVOIRE; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; LEUKORRHEA; MAJOR CLINICAL STUDY; SENSITIVITY ANALYSIS; URINARY BURNING; URINARY TRACT DISEASE; VAGINA CANDIDIASIS; VAGINAL PRURITUS;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; COTE D'IVOIRE; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; LEUKORRHEA; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TRIAZOLES; YOUNG ADULT;

CANDIDA ALBICANS; FUNGI;

EID: 84862009370     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2011.11.005     Document Type: Article

References (39)

1. Amouri I., Abbes S., Sellami H., Makni F., Sellami A., Ayadi A. La candidose vulvovaginale : revue. J Mycol Med 2010, 20:108-115.
2. Anane S., Kaouech E., Zouari B., Belhadj S., Kallel K., Chaker E. Les candidoses vulvovaginales : facteurs de risque et particularités cliniques et mycologiques. J Mycol Med 2010, 20:36-41.
3. Bauters T.G.M., Dhont M.A., Temmerman M.I.L., Nelis H.J. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002, 187:569-574.
4. Benchellal M., Guelzim K., Lemkhente Z., Jamili H., Dehainy M., Rahali Moussaoui D., et al. La candidose vulvovaginale à l'hôpital militaire d'instruction Mohammed V (Maroc). J Mycol Med 2011, 21:106-112.
5. Chassot F., Negri M.F.N., Svidzinski A.E., Donatti L., Peralta R.M., Svidzinski T.I.E., et al. Can intra-uterine contraceptive devices be a Candida albicans reservoir?. Contraception 2008, 77:355-359.
6. Dorrell L., Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self-treatment with non-prescribed triazoles. Sex Transm Infect 2002, 78:308.
7. El-Din S., Reynolds T.M., Ashbee H.R., Barton R.C., Evans E.G. An investigation into the pathogenesis of vulvovaginal candidosis. Sex Transm Infect 2001, 77:179-183.
8. Erja C. Trends in antifungal susceptibility among swedish candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27 - a reference method. J Clin Microbiol 2001, 39:4181-4183.
9. Grigoriou O., Baka S., Makrakis E., Hassiakos D., Kapparos G., Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121-125.
10. Hospenthal D.R., Murray C.K., Rinaldi M.G. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004, 48:153-160.
11. Jindal N., Gill P., Aggarwal A. An epidemiological study of vulvovaginal candidiasis in women of childbearing age. Indian J Med Microbiol 2007, 25:175-176.
12. Jin-Sol L., Jong H.S., Kyungwon L., Mi-Na K., Bo-Moon S., Young U. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007, 48:779-786.
13. Karaer A., Boylu M., Avsar A.F. Vaginitis in Turkish women: symptoms, epidemiologic-microbiologic association. Eur J Obstet Gynecol Reprod Biol 2005, 121:211-215.
14. Khan Z.U., Chandy R., Metwali K.E. Candida albicans strain carriage in patients and nursing staff of an intensive care unit: a study of morphotypes and resistotypes. Mycoses 2003, 46:476-486.
15. Khosravi A.R., Shokri H., Mansouri P., Katiraee F., Ziglari T. Candida species isolated from nails and their in vitro susceptibility to antifungal drugs in the department of dermatology (University of Tehran, Iran). J Mycol Med 2008, 18:210-215.
16. Klepser M.E. Antifungal resistance among Candida species. Pharmacotherapy 2001, 21:124-132.
17. Mathema B., Cross E., Dun E., Park S., Bedell J., Slade B., et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001, 33:23-27.
18. Menan H., Ekaza E., Messou E., Adoubryn K., Yavo W., Kiki-Barro P., et al. Recherche de Candida dubliniensis chez des patients VIH+à Abidjan (Côte d'Ivoire). J Mycol Med 2008, 18:228-233.
19. Moreira D., Paula C.R. Vulvovaginal candidiasis. Int J Gynecol Obstet 2006, 92:266-267.
20. Nyirjesy P., Seeney S.M., Grody M.H.T., Jordan C.A., Buckley H.R. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995, 173:820-823.
21. Nyirjesy P., Sobel J.D. Vulvovaginal candidiasis. Obstet Gynecol Clin N Am 2003, 30:671-684.
22. Panizo M.M., Reviakina V., Dolande M., Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 2009, 47:137-143.
23. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
24. Pfaller M.A., Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
25. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155-2162.
26. Rieu P., Eloy O., Bertout S., Mallié M., Bain P., Blanc V. Sensibilité comparée par CLSIS, EUCAST, E-test et ATB Fungus 2 des souches de Candida sp. isolées au cours d'une enquête épidémiologique sur les candidémies dans des hôpitaux non universitaires. J Mycol Med 2009, 19:94-103.
27. Runyoro D.K.B., Matee M.I.N., Ngassapa O.D., Joseph C.C., Mbwambo Z.H. Screening of Tanzanian medicinal plants for anti-Candida activity. BMC Com Alternat Med 2006, 30:6-11.
28. Rylander E., Berglund A.L., Krassny C., Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004, 80:54-57.
29. Sandra S.R., Rudolph P.G., Shawn A.M., Richard J.H., Daniel J.D., Michael A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155-2162.
30. Saporiti A.M., Gomez D., Levalle S., Galeano M., Davel G., Vivot W., et al. Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use. Rev Argent Microbiol 2001, 33:217-222.
31. Senterre J.M., Carpentier M., Foidart J.M. Prévalence des différentes espèces de Candida au niveau vaginal dans la région Liégeoise. Rev Med Liege 2005, 60:882-884.
32. Skrodeniene E., Dambrauskiene A., Vitkauskiene A. Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 2006, 42:294-299.
33. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
34. Sobel J.D., Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997, 24:649-652.
35. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004, 351:876-883.
36. Sobel J.D., Zervos M., Reed B.D., Hooton T., Soper D., Nyirjesy P., et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003, 47:34-38.
37. Spinillo A., Capuzzo E., Gulminetti R., Marone P., Colonna L., Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997, 176:138-141.
38. St-Germain G., Laverdie M., Pelletier R., Bourgault M., Libman M., Lemieux C. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001, 39:949-953.
39. Verghese S., Padmaja P., Asha M., Elizabeth S.J., Anitha A., Kundavi K.M., et al. Prévalence, répartition des espèces et sensibilité antifongique de levures vaginales chez les femmes infertiles. Indian J Pathol Microbiol 2001, 44:313-314.